The ring had momentum. Oura, the Finnish maker of the smart ring that tracks sleep and heart rate, had just introduced the Oura Ring 5, pushed its paying membership to 5.7 million people and told investors it expected revenue to grow about 90% for the fiscal year. Its shares were meant to begin trading on the Nasdaq on a Wednesday morning. Instead, the company announced a delay.
Oura said in late September that it was postponing its U.S. initial public offering, citing uncertainty in the IPO market and doing so, in the company’s phrase, despite strong demand. The decision made Oura the highest-profile of a string of companies to pull back from listings as markets turned volatile. Analysts had viewed its debut as a test of investor appetite for high-growth consumer hardware, and the test never happened.
The mechanics of the deal had been set. Oura planned to sell 50 million shares at a price range of $40 to $44, raising up to $2.2 billion, with nearly three-quarters of the shares sold by existing investors. At the top of the range, the offering would have valued the company at about $15.6 billion on a fully diluted basis. It was expected to price on a Tuesday and begin trading the following day.
The delay was not about Oura’s numbers, which were strong. It was about the market around it. A spike in bond yields, fears of further rate increases by the Federal Reserve and a reassessment of the enormous spending on AI infrastructure had all cooled investor appetite for new listings, according to Renaissance Capital and others who track the market. The IPO market had a solid start to the year, then tailed off in the third quarter. September, usually one of the busiest months for new listings, stayed quiet.
Oura’s chief executive, Tom Hale, framed the decision as one of choice rather than retreat. The company aims to deliver an extraordinary IPO for its employees and investors, he said in a statement, and it has the luxury of choosing its moment. Oura has filed a registration statement with the Securities and Exchange Commission that has not yet been declared effective, which keeps its options open.
The company came to the offering from a position of unusual strength for a hardware maker. Founded more than a decade ago in Finland, Oura built a following among athletes and celebrities, and its rings have appeared on the hands of Lady Gaga and the tennis player Coco Gauff. It raised more than $900 million last year at a valuation of roughly $11 billion, money it said it would use to develop more health features.
But the delay carries a larger message about the market for AI-era consumer hardware. Oura has been held up as a model of how a device maker can turn a physical product into a subscription business, with a trove of health data that Wall Street could value like software. Its retreat suggests that even that story is not immune to the same forces weighing on everything else: when money costs more, the premium investors will pay for future growth shrinks.
The delay is also a signal for a corner of the market that has spent the year chasing the next device. Oura had been cast as one of the first consumer hardware companies to ride the AI wave to a public listing, a proof point that a ring with sensors and a subscription could command software-style multiples. Its retreat leaves that thesis unproven, and it adds to the pressure on venture-backed hardware makers that had been counting on the public markets for an exit just as their backers began asking when the returns would arrive.
The context makes the timing uncomfortable. Oura’s delay came as Anthropic, the AI lab, pushes toward what could be one of the largest IPOs ever, and as the broader market digests whether the AI buildout’s spending can be sustained. Analysts said the IPO window is not closed, but it has become more selective, and companies now need stable markets to reach the valuations they want.
For Oura, the wait is not costless. A delayed listing leaves the company without the currency of public shares while rivals and the broader wearables market keep moving, and it leaves employees and early investors holding illiquid stock for longer than planned. The company has cash and a growing subscriber base, and in a market this skittish, patience can look like its own kind of strength.
The question Oura’s delay poses is not whether it will eventually list, but what price the market will offer when it does. A company that priced at $44 a share in September may find that number harder to reach in a colder season. Oura is betting it can choose its moment. The market, for its part, is signaling that the moment may not belong to the company alone.
